Loading organizations...
§ Private Profile · Or Yehuda, Israel
technology incubator supporting pre-seed and early-stage life sciences startups, focused on medical innovations.
Key people at Incentive Accelerator, Peregrine Ventures.
Incentive Accelerator, operated by Peregrine Ventures, is a technology incubator based in Or Yehuda, Israel, supporting pre-seed and early-stage life sciences startups with infrastructure, business development, and investment. Leveraging Peregrine's venture capital expertise, the incubator focuses on medical devices, pharma, biotech, and digital health. Peregrine Ventures manages over $300 million in assets under management across 75 portfolio companies, while Incentive Accelerator has established 60 companies, with 34 active and an aggregate graduate value of $5 billion. Recent initiatives include a consortium to invest over $90 million with partners such as Bristol-Myers Squibb, BD, and Merck. The organization collaborates with entrepreneurs and institutions like Tel Aviv University and is led by Eyal Lifschitz, Boaz Lifschitz, and Lior Shahory. Incentive Accelerator was founded in 2002 by Peregrine Ventures.
Key people at Incentive Accelerator, Peregrine Ventures.
Incentive Accelerator, operated by Peregrine Ventures, is Israel's first privatized incubator dedicated to advancing healthcare innovation by investing in and supporting early-stage medical technologies that improve patients' quality of life.[1][2] Controlled by Peregrine Ventures, a global specialist in transformative medical technologies, it focuses on devices, pharma, and biotech sectors, providing lifecycle support from pre-seed through growth stages via dedicated funds like the Incentive Incubator, Peregrine Fund (early/mid-stage), and Peregrine Growth Fund.[1][5] Its mission emphasizes deep industry knowledge, synergetic strategies, and hands-on guidance to help entrepreneurs build disruptive companies, forge alliances, recruit teams, and bring innovations to market, significantly impacting Israel's startup ecosystem by bridging ideation to commercialization.[1][2]
Incentive emerged as Peregrine Ventures' dedicated pre-seed and incubator arm, positioning itself as Israel's pioneering privatized incubator focused exclusively on healthcare.[1][2][5] Peregrine Ventures, the controlling entity, has evolved into a healthcare investment powerhouse with funds tailored to different growth stages, drawing on decades of experience in medical technologies.[1][5] A pivotal moment came with the strategic partnership announcement with Merck KGaA in 2023 (or earlier, per records), where Merck joined as a partner in the Incentive Incubator, providing startups access to pharma insights, investments, clinical resources, and global networks to accelerate success in life sciences and bioconvergence.[4] Led by figures like Lior Shahory, CEO of Incentive and general partner at Peregrine, this setup has humanized Peregrine's approach by embedding operating expertise from day one.[1][4]
Incentive rides the wave of healthtech and biotech convergence, capitalizing on Israel's medtech hub status amid rising demand for patient-centric innovations in devices and pharma.[1][2] Timing aligns with global pushes for faster drug development and bioconvergence, amplified by post-pandemic investments in resilient healthcare supply chains.[4] Market forces like aging populations, AI-driven diagnostics, and pharma giants scouting startups favor its model, as seen in Merck's entry for early co-development opportunities.[4] It influences the ecosystem by democratizing privatized incubation, fostering local-global collaborations, and accelerating "life-changing" tech from Israel to worldwide markets, strengthening the venture pipeline for Peregrine's broader funds.[1][5]
Incentive's trajectory points to expanded partnerships with pharma leaders, fueling more pre-seed breakthroughs into growth-stage exits amid booming healthtech funding.[4][5] Trends like bioconvergence, personalized medicine, and regulatory streamlining will shape its path, potentially scaling via Peregrine's growth vehicles for higher AUM and IPO/M&A velocity. Its influence may evolve into a blueprint for hybrid incubator-VC models, amplifying Israel's role in global medtech while delivering sustained returns—proving that strategic control from Peregrine turns incubator bets into ecosystem wins.[1][2]
